The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Body Shop Founder's Legacy

Back to News Homepage

Next

HCV's Gene Unraveling Secret Discovered

Lowering Hep C Viral Load in Non Responders

Print this page

Pharmasset’s nucleoside polymerase inhibitor, R7128, will begin a new round of testing following its positive Phase 1 results. In addition to appearing safe and well-tolerated, R7128 is showing potential to lower Hepatitis C viral load in non-responders.

AFX News Limited

Roche’s US partner Pharmasset says hepatitis C trial drug decreases virus level
09.10.07, 10:37 AM ET
www.forbes.com

ZURICH (Thomson Financial) – Roche Holdings AG’s US partner Pharmasset Inc said hepatitis C trial drug R7128 successfully lowered the level of the virus in patients who failed to respond to interferon therapy.

The phase I clinical study was carried out for 14 days on 40 patients, with R7128 showing ‘potent antiviral activity’ as well as being safe and well tolerated, Pharmasset (nasdaq: VRUS – news – people ) said. Dosages used in the study were 750 mg or 1500 mg.

New Jersey based Pharmasset is collaborating with Roche to develop the drug, and based on the results of the trial will start a 28-day study of R7128 in combination with interferon Pegasys plus Copegus.

R7128 is classed as a nucleoside polymerase inhibitor, a new generation of antivirals being developed to treat hepatitis C patients.

[email protected]

No Comments - be the first!
Share
Share

Previous

Body Shop Founder's Legacy

Back to News Homepage

Next

HCV's Gene Unraveling Secret Discovered

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.